Loading clinical trials...
Loading clinical trials...
A Phase 1 Randomized, Single-Blind, Three-Arm, Staggered Parallel Study to Assess the Safety, Tolerability, and Pharmacokinetics of Atorvo+™ in Healthy Adult Participants
Conditions
Interventions
Atorvo+™ (Arm1)
Atorvo+™ +CBD (Arm 2)
+1 more
Locations
1
Australia
Nucleus Network
Melbourne, Australia
Start Date
January 28, 2025
Primary Completion Date
May 14, 2025
Completion Date
June 10, 2025
Last Updated
December 19, 2025
NCT07451873
NCT06380322
NCT06216847
NCT07149688
NCT06759805
NCT06568471
Lead Sponsor
Indication Bioscience LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions